Clinical trial · Observational
Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease. NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy. The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse. The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management. This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer (GC) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Molecular Analysis | — | UNRESOLVED | — |
| Next-generation Sequencing | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next-generation sequencing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Уoung-adult age group
- description
- age 18-44 yr.
- interventionNames
- Diagnostic Test: Next-generation sequencing
- label
- Middle-aged group
- description
- age 45-59 yr.
- interventionNames
- Diagnostic Test: Next-generation sequencing
- label
- Eldery age group
- description
- age 60-74 yr.
- interventionNames
- Diagnostic Test: Next-generation sequencing
- label
- Senior age group
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed diagnosis of gastric cancer * The resectable stage of the disease (I-III) * Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes * Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy * Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification) Exclusion Criteria: * The presence of metastases in distant organs at the time of diagnosis * Primary-multiple tumors * Diagnostic and palliative surgery * Incomplete clinical data * Pregnancy
References
Publications (0)
Data not yet available